Catalyst Pharmaceuticals announced the U.S. commercial launch of AGAMREE oral suspension 40 mg/mL for the treatment of Duchenne Muscular Dystrophy in patients aged two years and older. Following the U.S. Food and Drug Administration approval on October 26, 2023, AGAMREE is now available by prescription and dispensed throughout the United States through a specialty pharmacy network.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CPRX:
- Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
- ‘Time to Hit Buy,’ Says Bank of America About These 3 Stocks
- BofA starts ‘unique aggregator’ Catalyst Pharmaceuticals with a Buy
- Catalyst Pharmaceuticals initiated with a Buy at BofA
- Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference
